Swiss maker of titanium plates and screws for surgical fixation of small and mid-sized bones.
Swiss maker of titanium plates and screws for surgical fixation of small and mid-sized bones.
Sells implants to hospitals one operation at a time, with its instrument sets placed on loan so surgeons train on its system and keep using it; it sells directly in its main markets and through distributors elsewhere. Based in Basel, Switzerland.
In one line: A small Swiss extremities-trauma implant specialist.
Moat: narrow (switching costs, brand, distribution). Surgeon familiarity with instrument sets and distribution in a niche extremities segment.
Headquarters: Basel, Switzerland · Founded: 1997 · Employees: 1,337
Size Medartis (MED.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $1.86B, the 95th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 114.80 on 18 Nov 2026.
Performance Over six months the shares gained 46.8%, against +1.5% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 29.9% over the last twelve months (peer median +9.6%); the operating margin is 1.6% (peer median 14.6%).
Valuation It trades at 72.8× forward earnings against a peer median of 21.1× (most expensive of 17).
Capital Return on invested capital runs 6.3 points below its cost of capital (7.2% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 307M | CHF 269M | CHF 225M | CHF 212M | CHF 183M |
| Revenue growth | — | +20% | +6% | +16% | — |
| Gross profit | CHF 238M | CHF 186M | CHF 162M | CHF 152M | CHF 135M |
| EBITDA | CHF 33.9M | CHF 25.6M | CHF 35.2M | CHF 32.4M | CHF 16.2M |
| Net income | CHF 14.9M | CHF 8.35M | CHF 3.53M | CHF 619,000 | -CHF 5.78M |
| Free cash flow | CHF 1.21M | CHF 12.3M | CHF 21.0M | CHF 5.03M | -CHF 19.4M |
| Capital expenditure | CHF 35.2M | CHF 25.5M | CHF 11.1M | CHF 18.8M | CHF 18.8M |
| Total debt | n/a | CHF 158M | CHF 121M | CHF 42.2M | CHF 52.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Medartis MED.SW | $1.86B | +47% | +30% | 2% | 72.8× | n/a |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
| Zimmer Biomet ZBH | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MED.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.9% | -4.4% | highest of 21 |
| 6-month return | +46.8% | +1.5% | 2nd highest of 20 |
| Distance from 52-week high | -0.2% | -27.0% | highest of 21 |
| Revenue growth (TTM) | +29.9% | +9.6% | 5th highest of 21 |
| Operating margin | 1.6% | 14.6% | 4th lowest of 21 |
| Forward P/E | 72.8× | 21.1× | most expensive of 17 |
| ROIC minus cost of capital | -6.3 pp | -0.6 pp | 5th lowest of 21 |
| EV / EBITDA | 51.6× | 15.5× | 3rd most expensive of 16 |
| Net debt / EBITDA | 5.4× | -0.9× | most indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |